omega-n-methylarginine has been researched along with avapro in 1 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 1,369 | 385 | 495 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allard, SE; Browne, DL; Cummings, MH; Meeking, DR; Munday, JL; Shaw, KM | 1 |
1 trial(s) available for omega-n-methylarginine and avapro
| Article | Year |
|---|---|
Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial.
Topics: Acetylcholine; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Indomethacin; Infusions, Intra-Arterial; Irbesartan; Male; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Tetrazoles; Vasoconstriction; Vasodilator Agents | 2006 |